Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Apr 24;11(9):1438.
doi: 10.3390/cells11091438.

Fas/CD95 Signaling Pathway in Damage-Associated Molecular Pattern (DAMP)-Sensing Receptors

Affiliations
Review

Fas/CD95 Signaling Pathway in Damage-Associated Molecular Pattern (DAMP)-Sensing Receptors

Gael Galli et al. Cells. .

Abstract

Study of the initial steps of the CD95-mediated signaling pathways is a field of intense research and a long list of actors has been described in the literature. Nonetheless, the dynamism of protein-protein interactions (PPIs) occurring in the presence or absence of its natural ligand, CD95L, and the cellular distribution where these PPIs take place render it difficult to predict what will be the cellular outcome associated with the receptor engagement. Accordingly, CD95 stimulation can trigger apoptosis, necroptosis, pyroptosis, or pro-inflammatory signaling pathways such as nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB) and phosphatidylinositol-3-kinase (PI3K). Recent data suggest that CD95 can also activate pattern recognition receptors (PRRs) known to sense damage-associated molecular patterns (DAMPs) such as DNA debris and dead cells. This activation might contribute to the pro-inflammatory role of CD95 and favor cancer development or severity of chronic inflammatory and auto-immune disorders. Herein, we discuss some of the molecular links that might connect the CD95 signaling to DAMP sensors.

Keywords: CD95; apoptosis; auto-immunity; inflammasome; necroptosis; pyroptosis; sting.

PubMed Disclaimer

Conflict of interest statement

P.L. is involved in patents protecting the use of CD95 or CD95L in chronic inflammatory disorders and cancers (WO2014118317; WO2015189236; WO2015158810; WO2015104284; WO2017149012; WO2018130679). The other authors declare no conflict of interest.

Figures

Figure 1
Figure 1
CD95 stimulation and potential links with inflammasome activation. At least three molecular complexes could occur upon CD95 engagement to trigger either apoptosis (pink circle), inflammation (green circle), or necrosis (blue circle). Apoptotic and necroptotic complexes control each other and the inflammatory complex (red lines). Necroptosis and pyroptosis signaling pathways lead to the break of the plasma membrane. IAPs also control an additional complex and these members are known to participate in the TNF-R-mediated signaling pathway. The NLRP3 inflammasome, which is activated by signal 1 + 2 is depicted. (GsdmD = Gasdermin D).
Figure 2
Figure 2
Representation of ion channels involved in the inflammasome activation. Different plasma membrane or endoplasmic reticulum ion channels have been involved in ion fluxes (black arrows) responsible for the signal 2 activating the inflammasome.

References

    1. Kurma K., Boizard-Moracchini A., Galli G., Jean M., Vacher P., Blanco P., Legembre P. Soluble CD95L in cancers and chronic inflammatory disorders, a new therapeutic target? Biochim. Biophys. Acta Rev. Cancer. 2021;1876:188596. doi: 10.1016/j.bbcan.2021.188596. - DOI - PubMed
    1. Guegan J.P., Ginestier C., Charafe-Jauffret E., Ducret T., Quignard J.F., Vacher P., Legembre P. CD95/Fas and metastatic disease: What does not kill you makes you stronger. Semin. Cancer Biol. 2019;60:121–131. doi: 10.1016/j.semcancer.2019.06.004. - DOI - PubMed
    1. Madkaikar M., Mhatre S., Gupta M., Ghosh K. Advances in autoimmune lymphoproliferative syndromes. Eur. J. Haematol. 2011;87:1–9. doi: 10.1111/j.1600-0609.2011.01617.x. - DOI - PubMed
    1. Lenardo M.J., Oliveira J.B., Zheng L., Rao V.K. ALPS-ten lessons from an international workshop on a genetic disease of apoptosis. Immunity. 2010;32:291–295. doi: 10.1016/j.immuni.2010.03.013. - DOI - PMC - PubMed
    1. Oliveira J.B., Bleesing J.J., Dianzani U., Fleisher T.A., Jaffe E.S., Lenardo M.J., Rieux-Laucat F., Siegel R.M., Su H.C., Teachey D.T., et al. Revised diagnostic criteria and classification for the autoimmune lymphoproliferative syndrome (ALPS): Report from the 2009 NIH International Workshop. Blood. 2010;116:e35–e40. doi: 10.1182/blood-2010-04-280347. - DOI - PMC - PubMed

Publication types